Healthcare companies can register for the drug company’s new “marketplace,” which stocks key medications in short supply, according to a Feb. 14 post on X. The portfolio includes amoxicillin-potassium clavulanate, cefdinir, etoposide, capecitabine, irbesartan and budesonide inhalation.
Mr. Cuban has previously indicated a focus on injectables that often fall into shortage. The company is still building its $11 million drug manufacturing plant in Dallas, which is expected to also ease shortages.
More than 4,000 medications are available through the marketplace, Mr. Cuban told Becker’s, which serves hospitals, retail pharmacies, clinics, post-acute care facilities and surgery centers.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.